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A B S T R A C T
Background
Turner syndrome (TS) affects about one in 1500 to 2500 live-born females. One of the most prevalent and salient features of the
syndrome is extremely short stature. Untreated women are approximately 20 to 21 cm shorter than normal women within their
respective populations. Recombinant human growth hormone (hGH) has been used to increase growth and final height in girls who
have Turner syndrome.
Objectives
To assess the effects of recombinant growth hormone in children and adolescents with TS.
Search methods
MEDLINE, EMBASE, The Cochrane Library, LILACS, BIOSIS, Science Citation Index and reference lists were used to identify
relevant trials.
Selection criteria
Randomised controlled trials were included if they were carried out in children with TS before achieving final height. Growth hormone
had to be administered for a minimum of six months and compared with a placebo or no treatment control condition.
Data collection and analysis
Two reviewers assessed studies for inclusion criteria and formethodological quality. The primary outcomes were final height and growth.
Secondary outcomes included bone age, quality of life, cognitive performance, and adverse effects.
Main results
Four RCTs that included 365 participants after one year of treatment were included. Only one trial reported final height in 61 treated
women to be 148 cm and 141 cm in 43 untreated women (mean difference (MD) seven cm, 95% CI 6 to 8). Short-term growth
velocity was greater in treated than untreated girls after one year (two trials, MD three cm per year, 95% CI 2 to 4) and after two
years (one trial, MD two cm per year, 95% CI 1 to 2.3). Skeletal maturity was not accelerated by treatment with recombinant growth
hormone (hGH). Adverse effects were minimally reported.
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Authors’ conclusions
Recombinant human growth hormone (hGH) doses between 0.3 to 0.375 mg/kg/wk increase short-term growth in girls with Turner
syndrome by approximately three (two) cm in the first (second) year of treatment. Treatment in one trial increased final height by
approximately six cm over an untreated control group. Despite this increase, the final height of treated women was still outside the
normal range. Additional trials of the effects of hGH carried out with control groups until final height is achieved would allow
better informed decisions about whether the benefits of hGH treatment outweigh the requirement of treatment over several years at
considerable cost.
P L A I N L A N G U A G E S U M M A R Y
Recombinant growth hormone for children and adolescents with Turner syndrome
Turner syndrome (TS) is a genetic disorder affecting the sexual development and appearance of girls and women. Women with TS are
much shorter than other women (by about 21 cm or eight inches). To try to overcome slow growth, recombinant growth hormone
(hGH) has been given. The hormone is injected under the skin several times a week until final adult height is achieved. The review found
some evidence that hGH does increase short-term growth in girls with TS and adult height (an increase of perhaps five centimeters
or two inches). However, girls treated with hGH are still substantially shorter than other women as adults. Final height in 61 treated
women was 148 cm and 141 cm in 43 untreated women.
B A C K G R O U N D
Description of the condition
Turner syndrome (TS) is the most common sex-chromosome ab-
normality in females and affects approximately three percent of fe-
males conceived (Saenger 1996). However, as there is a high spon-
taneous miscarriage rate, TS affects one in 1500 to 2500 live-born
females (Saenger 1996). Affected individuals either have a single
X chromosome (45,X) or display chromosomal mosaicism (45,X/
46,XX). Chromosomal mosaicism is a condition in which some
cells have one chromosome constitution and others another. This
results in an individual having two or more genotypically distinct
cell lines. This condition results in individuals who are phenotypi-
cally female (in other words whose appearance is female), but who
have a very high likelihood of ovarian failure. Girls and women
with TS may present with any of a number of physical abnormali-
ties (for example, growth failure, gonadal dysgenesis, abnormalities
of some internal organs, “square” appearance) as well as some cog-
nitive difficulties such as difficulties in non-verbal problem solving
(for example, mathematics) or visual-spatial processing, although
overall intelligence is generally normal (Saenger 1996).
Turner syndrome: effects on height
Turner Syndrome (TS) is one of the most common organic causes
of short stature in girls and between 80 and 100 percent of girls
with TS will have growth failure (Saenger 1996). Short stature is
the most common finding in TS and is almost always present even
in patients who do not display other clinical features. However,
short stature may not be present if the girl has inherited her re-
maining X chromosome from a tall parent.
TS usually involvesmild intrauterine growth restriction (about one
standard deviation [SD] below normal), decreased growth rates
during infancy and childhood (generally about two SD below the
normal mean) and pronounced lack of pubertal growth resulting
in height approximately four SD below the mean at about age 14
(Ranke 1988; Saenger 1996). Thereafter, growth continues slowly
back toward the norm with final height about 2.6 SD below the
mean of normal adult women (Ranke 1988). The growth phase
is more prolonged than in normal girls not generally being com-
pleted before the end of the second decade of life. Although the
mechanismof growth failure inTS is notwell understood, it “prob-
ably results from an impaired response to growth hormone com-
bined with an underlying skeletal dysplasia” (Rochiccioli 1994).
Most studies suggest that the adult height of untreated girls with
TS generally averages approximately 143 cm to 144 cm (56 in
to 57 in), however, individual studies of final height in TS have
reported means ranging from 136 cm to 147 cm (Rochiccioli
1994). This is approximately 20 to 21 cm (eight inches) shorter
than normal women within their respective populations. Final
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height of untreated girls with TS is related to the average of the
parents’ heights. Although the mean final height of groups of girls
with TS generally falls within a fairly narrow range, there is a great
deal of variability among individuals (Rochiccioli 1994).
Description of the intervention
Growth hormone has been administered in girls with Turner syn-
drome (TS) as well as in children with other aetiologies for growth
failure. Although TS does not involve a deficiency of growth hor-
mone, it is believed that growth failure may be related to an im-
paired response to growth hormone and that administration of
additional growth hormone may enhance growth in children and
adolescents with TS (Gault 2001).
Recombinant human growth hormone (hGH) has been available
since 1985, shortly after growth hormone from cadaveric human
pituitaries was withdrawn from use because of its association with
the transmission of Creutzfeldt-Jacob disease. Recombinant hu-
man growth hormone (somatropin) is produced by recombinant
DNA technology and has a sequence identical to that of human
growth hormone. Somatropin is available from several manufac-
turers under several different brand names. The advent of recom-
binant hGH has meant that hGH is far more available and hGH
has been widely used to treat various growth disorders including
TS (Gault 2001).
Recombinant human growth hormone is usually prescribed in as-
sociation with a paediatric endocrinologist or a general paediatri-
cian with a special interest in endocrinology. It is prescribed in
milligrams (mg) or International Units (IU) (3 IU = 1mg) accord-
ing to body weight or body surface area and is self administered
(or given by a parent) at home usually as a subcutaneous injection
generally six to seven times per week. Whether dose is computed
by weight or body surface area can have a significant effect on the
dose given and is particularly relevant in older girls with TS who
may have problems with weight gain. Among younger girls (age
5) a dose based on surface area was reported to be as much as
33% greater than one based on weight, whereas among older girls
(age 15) the dose based on surface area could be as much as 10%
less (Betts 1999). The dose of hGH generally recommended for
use in TS is not often specified, but a dose of 0.375 mg/kg/week
has been suggested by the American Association of Clinical En-
docrinologists (AACE) (Gharib 1998). This dose is approximately
double that used in children with growth hormone deficiency. To
more closely approximate the natural daily fluctuations in hGH,
the injections are usually given at night.
In growth hormone deficiency, hGH is given as replacement ther-
apy (that is, a physiological dose), in which it is intended to sup-
plement low levels of naturally occurring hGH up to normal lev-
els. However, in TS, hGH is given at supra physiological levels -
levels considerably higher than a replacement dose. The logic in
administering supra physiological doses is generally that children
with TS have a growth deficiency, but not a hormone deficiency,
and therefore have some lack of sensitivity to the hormone.
Growth hormone is generally prescribed for a number of years -
from the diagnosis of the growth deficit until growth is complete.
For an individual child how long this would be will depend upon
when TS is diagnosed and whether the child, parents, and physi-
cian deem treatment necessary. However, even in congenital dis-
orders of growth such as TS, diagnosis may not occur until the
child is several years old.Most trials of hGHhave been of relatively
short duration (for example, five years), but in practice in many
children therapy could continue for as long as 12 years or more.
Not all girls with TS will need hGH treatment. A minority will
reach a final height within the normal range without treatment and
a few will be diagnosed too late for effective treatment. However,
it has become common practice to treat girls with TS with hGH
and often with an anabolic steroid (for example, oxandrolone) as
well.
Oestrogen is commonly administered in TS to promote puberty,
but there does not appear to be any evidence that it is a growth-
promoting agent - indeed, the opposite, as oestrogen therapy that
was started at younger ages resulted in reduced final heights com-
pared with girls in whom oestrogen was started later (for example,
after age 14) (Saenger 1996). It is now generally thought that it is
important to administer hGH for as long as possible before start-
ing oestrogen therapy.
Adverse effects of the intervention
BritishNational Formulary recommendations are that growth hor-
mone therapy is contraindicated in cases of tumour activity and
should not be used after renal transplant in seriously ill children
or for growth promotion in children with closed epiphyses (BNF
2002). Side effects can include headache, visual problems, nau-
sea and vomiting, fluid retention (peripheral oedema), arthralgia,
myalgia, paraesthesia, antibody formation, hypothyroidism and
reactions at injection site. There has been concern that growth
hormone would induce new tumours or increase the likelihood
of tumour relapse. Reports suggest, however, that the risk of new
tumours or tumour recurrence is not elevated in children treated
with growth hormone who have no other increased risk factors
(Blethen 1996; Frisch 1997; GH Soc 2001). Antibody forma-
tion is generally not of clinical consequence, although in some pa-
tients this can be associated with growth rate deceleration (Blethen
1996).
How the intervention might work
Evaluating effects of growth hormone
Height (and growth velocity, see below) is often reported in length
units (cm) or in standard deviation scores (SDS).
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The standard deviation is ameasure of the variation of observations
around the mean. Heights of populations of adults or children
generally form normal distributions such that 95.4% of a popu-
lation will have heights that fall within two standard deviations
(SD) from the mean. Individual observations can be compared
with heights corresponding to points on the height distribution
for a particular age to determine how a child’s (or adult’s) height
compares with their peers. Standard deviation score is defined by
the formula: actual height minus mean height for age divided by
standard deviation of height for age. Standard deviation scores us-
ing controlled data collected from an appropriate population base
allow comparison of measures independent of age. In this system
the normal population mean is zero and a normal SD score will lie
between approximately -2 and +2 SD. A healthy individual’s SDS
will not change during the growth years. Increased SDS implies
catch-up growth and a decrease implies growth failure.
The best measure of how recombinant growth hormone (hGH)
affects growth is to measure final adult height (in cm or SDS).
Measuring final height requires that the child has finished growing.
The most reliable measures of final height use multiple criteria to
determine that growth is complete or nearly complete. Generally,
it is considered that children have completed or nearly completed
their growth when their growth rate within a year has slowed to
less than some specified amount (for example, 1 to 2 cm) and
skeletal maturity assessed by radiographs of the wrist and hand
indicate that the epiphyses have closed (often expressed as bone age
greater than a certain value, for example, 14 to 15 years) (Frindik
1999). Acknowledging that measures may be taken before growth
is fully complete, ’near final height’ is sometimes reported. This is
a measure of height when it is presumed that growth is complete
as discussed above.
Although the overall effectiveness of hGH in treating short stature
is to be found in measures of final height, it has been argued that
short-term measures of growth are also of importance. Children
and parents may be concerned with whether growth within a cer-
tain time frame is comparable to that of a child’s peers. Velocity
may also be a better interim growth measure than height attained
at a particular age as it is independent of growth in previous years.
Growth velocity (GV) is a measure of the height gained (cm)
within a specified time period (usually a year). This outcome is
also often referred to as ’height velocity.’ Growth velocity can also
be considered in relation to a child’s age by considering growth
velocity relative to the distribution of growth velocities for chil-
dren of a particular age (growth velocity standard deviation score
- GVSDS). As with height, growth velocity SDS measures are de-
pendent upon the reference data used (Haeusler 1994).
Bone age is a measure of skeletal maturity. It is customarily de-
termined by examining the relative positions of the bones in the
left hand and wrist from a radiograph. The measurement of bone
age relative to chronological age is important in height prediction
models. In addition, bone age assessments are used to evaluate
when the epiphyses have closed and growth is complete. Growth
cannot occur after the epiphyses (ends of the long bones) have
closed. The interim assessment of bone age is important in deter-
mining whether treatment is advancing bone maturity. Acceler-
ated bone age in treated individuals would indicate that treatment
was shortening the growth period and might therefore have the
paradoxical effect of premature closure of the epiphyses and de-
creased final height. Therefore, if hGH were an effective growth
promoting agent without inducing premature skeletal maturity,
then there would be a lack of treatment effects on bone age.
It is of considerable interest to determine whether treatment with
hGH affects children’s sense of well-being or quality of life. A
number of measures have been designed to assess quality of life.
In addition, there are many measures of self-concept, psychosocial
functioning and so on that might be affected by hGH treatment.
Turner syndrome can include psychological or cognitive charac-
teristics. It is therefore of interest to determine whether hGH treat-
ment might affect cognitive functioning.
Existing evidence on the use of growth hormone in
Turner syndrome
Growth hormone has been used for some years in TS. Although
many consider that hGH has demonstrated beneficial effects in
increasing growth and height in girls with TS, the results from tri-
als have been variable. Within trials there is also variation among
individuals in response to treatment. Whether hGH is effective
in increasing height in patients with TS is still somewhat con-
troversial. How much height may be gained is also an important
consideration as hGH treatment is quite costly.
Costs
A recent review of the clinical and cost-effectiveness of recombi-
nant growth hormone in the UK (Bryant 2002) included a model
that suggested that approximately 97% of the cost of treating pa-
tients with Turner syndrome for short stature was drug (growth
hormone) cost. This model showed that mean total cost of treat-
ment assuming treatment for five years with a final height benefit
of 4.4 to 4.8 cm was approximately £63,000 (93,909 EURO) re-
sulting in an incremental cost per centimetre of final height gain
of approximately £16,000 to £17,500 (23,850 EURO to 26,090
EURO).
Why it is important to do this review
Although there have been some reviews of the use of recombinant
growth hormone in Turner syndrome (for example, Donaldson
1997; Guyda 1999), there have been no reviews that have used
systematic methods to locate and evaluate the best possible evi-
dence. For instance, existing reviews have not used methods that
exhaustively searched the available literature for relevant trials.
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Previous reviews have also included studies that have varied in
the interventions used. These results combine not only the effects
of hGH, but also in some cases effects of other concomitant in-
terventions such as oxandrolone. Although it may eventually be
demonstrated that height optimisation requires the use ofmultiple
interventions, it is initially valuable to evaluate the effectiveness of
hGH alone.
O B J E C T I V E S
To assess the effects of recombinant growth hormone on short-
term growth and final height in children and adolescents with
Turner syndrome.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials or quasi-randomised trials were in-
cluded. Trials had to evaluate one or more of the height or growth
outcomes described below.
For short-term growth outcomes, recombinant growth hormone
(hGH) should be administered for a minimum of six months. For
final height outcomes, hGH should be administered until final
height is achieved. Criteria used within trials for the attainment of
final height were accepted (for example, growth velocity less than
two cm per year). Trials that reported ’near final’ height (using
criteria that presume that growth is nearly complete, but being
more conservative in calling growth complete) were also included.
Types of participants
Participants were children/adolescents with Turner syndrome
(TS). The participants had to have TS confirmed by karyotype.
All TS karyotypes accepted within studies meeting other inclusion
criteria were included. All participants treated prior to closure of
epiphyses were included.
Types of interventions
The active intervention was recombinant human growth hormone
(hGH): that is, biosynthetic human growth hormone (somat-
ropin), with a sequence identical to that of human growth hor-
mone, marketed under any brand name.
The following comparisons were considered:
• administration of hGH for a minimum of six months
versus administration of placebo;
• administration of hGH for a minimum of six months
versus no treatment.
Human pituitary derived growth hormone is no longer used since
it was implicated in the transmission of Creutzfeldt-Jacob disease
in the 1980’s. There are no other forms of growth hormone cur-
rently used to promote height in humans.
Types of outcome measures
Primary outcomes
Outcomes focused on those deemed clinically relevant to children
withTurner syndromewith growth deficiencies and growth failure.
Trials for inclusion had to report a height or growth outcome.
Other outcomes specified below that were reported in the context
of growth or height were also included.
• final height: The gold standard outcome measure of
effectiveness of growth hormone treatment is final height (in cm
or height standard deviation [HtSDS] relative to a normal
population). Height is often reported in standard deviations
relative to some population. HtSDS gives an indication of height
relative to other children of the same age or relative to other
adults in the case of final height. HtSDS can also be reported
relative to a population with TS. Although this measure would
also indicate whether treated patients are taller than an untreated
TS sample or population, this would not be the best comparison
for evaluating a patient-relevant outcome. The most salient
comparison is how children and adults with TS compare in
height relative to the normal population with whom they
interact;
• short-term growth: Because many trials are of insufficient
duration to collect final height, short-term growth responses to
treatment including height standard deviation score at a point
prior to final height (HtSDS; or change in HtSDS over some
treatment period) and growth velocity (change in cm per
treatment interval; or velocity standard deviation score) have
been included. Short-term height gains may be important to
children and adolescents with TS whose growth tends to lag
behind that of their peers at a time when they may be
particularly sensitive to height comparisons with their peers.
• final height: The gold standard outcome measure of
effectiveness of growth hormone treatment is final height (in cm
or height standard deviation [HtSDS] relative to a normal
population). Height is often reported in standard deviations
relative to some population. HtSDS gives an indication of height
relative to other children of the same age or relative to other
adults in the case of final height. HtSDS can also be reported
relative to a population with TS. Although this measure would
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also indicate whether treated patients are taller than an untreated
TS sample or population, this would not be the best comparison
for evaluating a patient-relevant outcome. The most salient
comparison is how children and adults with TS compare in
height relative to the normal population with whom they
interact;
• short-term growth: Because many trials are of insufficient
duration to collect final height, short-term growth responses to
treatment including height standard deviation score at a point
prior to final height (HtSDS; or change in HtSDS over some
treatment period) and growth velocity (change in cm per
treatment interval; or velocity standard deviation score) have
been included. Short-term height gains may be important to
children and adolescents with TS whose growth tends to lag
behind that of their peers at a time when they may be
particularly sensitive to height comparisons with their peers.
Secondary outcomes
When they were reported, the following outcomes were extracted
from trials that reported a growth or height outcome described
above. Trials were not included if they reported one or more of
the following outcomes, but did not report a growth or height
outcome.
• bone age, a measure of skeletal maturity;
• quality of life or psychological adjustment assessed using
validated scales (Because no included trials reported quality of
life, but psychological measures such as self-concept were
reported, psychological adjustment was added as an outcome);
• measures of cognitive performance that were assessed using
validated instruments. For instance, these could include
measures of visual-spatial or mathematics performance;
• adverse effects such as benign intracranial hypertension,
slipped capital epiphyses, effects on glucose metabolism, and
incidence of malignant disease
Exclusion criteria
Randomised controlled trials that considered hGH against an-
other active treatment rather than placebo or no treatment were
excluded. The objective of the review was to consider the efficacy
of hGH as a growth promoting treatment. Trials that compared
hGH with other treatments known or presumed to affect growth
would not be informative about the fundamental efficacy of hGH.
Dose-response trials (which do not include a zero dose or placebo
group) were also excluded as they do not address whether hGH
works. Trials that compared hGH plus some other active treat-
ment against only the active treatment were also excluded. In this
type of design the effects of hGH may be different than when
hGH is administered alone. Because the aim was to evaluate the
effects of hGH, designs in which hGHmay interact with another
treatment were excluded.
Search methods for identification of studies
Electronic searches
Searches were not conducted for trials before 1980 because the
intervention (recombinant hGH) was not introduced until 1985.
Earlier trials using growth hormone derived from human pitu-
itary were not included as pituitary-derived growth hormone is no
longer used.
The following electronic databases were searched to identify rele-
vant trials:
• The Cochrane Library (Issue 4, 2005);
• MEDLINE (up to July 2006);
• EMBASE (up to June 2002);
• Science Citation Index (up to June 2006);
• BIOSIS (up to June 2006).
The MEDLINE search strategy was adapted for searches of EM-
BASE, TheCochrane Library andHMIC.Other databases that do
not have facilities for complex search strategies were searched us-
ing a combination of “growth hormone” and “Turner* syndrome”.
For a detailed search strategy, see Appendix 1
The following sources were searched for ongoing trials:
• National Research Register (Issue 3, 2006),
• Current Controlled Trials (http://controlled-trials.com/,
search 16 August 2006).
Searching other resources
The following sources were searched for grey literature: Web of
Knowledge Proceedings (the Institute for Science Information
Proceedings allow access to abstracts frompapers delivered at inter-
national conferences, symposia, seminars, colloquia, workshops,
and conventions; searched 16 August 2006), HealthManagement
Information Consortium (HMIC; this database focuses on com-
munity care and health systems management in the UK, Europe
and developing countries including journals, books, reports, offi-
cial publications and grey literature; searched 16 August 2006).
Experts were contacted for advice and peer review, and to identify
additional published and unpublished references. The following
pharmaceutical companies were contacted for additional trials:
Eli Lilly, Ferring, Novo Nordisk, and Pharmacia. No additional
studies were obtained from the pharmaceutical companies.
Bibliographies of related papers were assessed for relevant studies.
Data collection and analysis
Selection of studies
Titles, abstracts and keywords of all retrieved records were re-
viewed for inclusion. Full articles were retrieved for further as-
sessment if the information available suggested that the study
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was a randomised controlled trial that: 1) included children with
Turner syndrome (TS), 2) compared recombinant growth hor-
mone (hGH) with placebo or no treatment, and 3) assessed one or
more of the growth or height outcomes to be included. Full articles
were also retrieved for clarification if there was doubt about inclu-
sion eligibility. Inclusion criteria were assessed independently by
two reviewers (LB and JB or CC and JB) with any disagreements
resolved through discussion with a third reviewer (RM).
Data extraction and management
The following data were extracted using a data extraction form:
• general information: authors, reference, country, year of
publication, study design;
• intervention: dose, route, timing, control intervention
(placebo or no treatment), any other relevant treatments;
• participants: total number and number in comparison
groups, age, trial inclusion and exclusion criteria, height baseline
characteristics, setting;
• outcomes specified above;
• results for outcomes listed as reported within trials;
• trial characteristics: methodological (allocation to treatment
groups, blinding, baseline comparability, method of analysis and
adequacy of sample size, and attrition), general (generalisability,
appropriateness of outcome measures, inter centre variability,
conflicts of interest);
• quality assessment.
Data extraction was done by two reviewers ( LB and JB or CC
and JB) with any disagreements resolved through discussion with
a third reviewer (RM).
Assessment of risk of bias in included studies
The quality of included RCTs was judged primarily using Jadad
criteria (Jadad 1996). In particular, the following were assessed:
• adequacy of randomisation (was the study described as
randomised and was the method to generate randomisation
described and appropriate);
• adequacy of blinding (was the study described as double
blind and was the method of blinding described and
appropriate); and
• reporting of dropouts and withdrawals (were withdrawals
and dropouts described and quantified). Quality criteria were
assessed by two reviewers (CC and JB) with any disagreements
resolved through discussion.
Assessment of heterogeneity
In the event of substantial clinical or methodological or statistical
heterogeneity, study results will not be combined inmeta-analysis.
Heterogeneity was identified by visual inspection of the forest
plots, by using a standard χ2-test and a significance level of α
= 0.1, in view of the low power of such tests. Quantification of
heterogeneity was also be examined with I2, ranging from 0%
to 100% including its 95% confidence interval (Higgins 2002).
I2 demonstrates the percentage of total variation across studies
due to heterogeneity and will be used to judge the consistency of
evidence. I2 values of 50% and more indicate a substantial level of
heterogeneity (Higgins 2003). When heterogeneity is found, we
will attempt to determine potential reasons for it by examining
individual study characteristics and those of subgroups of themain
body of evidence.
Data synthesis
Data were summarised statistically if they were available, suffi-
ciently similar and of sufficient quality. Statistical analysis were
performed according to the statistical guidelines referenced in the
newest version of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2005).
When only one study reported an outcome, a mean difference
(MD) was reported.
Subgroup analysis and investigation of heterogeneity
There were insufficient data to allow for any subgroup analyses.
Should sufficient data in future permit, the following subgroup
analyses would be of interest:
• duration of treatment: fewer than two years, two to four
years, more than four and less than six years, more than six and
less than eight years, more than eight years;
• injection frequency: three times weekly versus six or seven
times weekly;
• treatment begun before puberty or after puberty.
Sensitivity analysis
There were insufficient data to allow for any sensitivity analyses.
Should sufficient data in future permit, the following sensitivity
analyses would be of interest:
• repeating the analysis excluding any unpublished studies (if
there are any);
• repeating the analysis taking account of study quality, as
specified above;
• repeating the analysis excluding any very large studies to
establish how they dominate the results.
• repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), country.
R E S U L T S
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Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
Across all searches 620 records were located (excluding duplicates).
Titles, abstracts and keywords of all records were reviewed by two
researchers (LB and JB or CC and JB). Any disagreements were
resolved through discussion. Reasons for exclusion included: stud-
ies not conducted in humans, studies conducted in adults, studies
in participants who do not have Turner syndrome (TS), studies
in which recombinant growth hormone (hGH) was not adminis-
tered, studies in which there was no untreated group, studies in
which there was no control group (single group studies), studies
in which groups were not randomised or quasi-randomised, stud-
ies in which there was no growth or psychological outcome, re-
views that were not conducted systematically, studies of hGHdose
(without a “zero dose” condition), duplicate publications, reports
of results from databases.
On the basis of review of the abstracts, 48 full records were re-
trieved. Abstracts had suggested that they would meet inclusion
criteria or there was a need for additional information to deter-
mine whether the study met inclusion criteria. These full reports
were assessed by two researchers (LB and JB or CC and JB). Ref-
erence citations are included for all retrieved references, either as
included or excluded studies. Based on review of the full reports
41 studies were excluded. These are listed in table Characteristics
of excluded studies with reasons for exclusion.
Four studies met the inclusion criteria. All were sponsored by or
received support from pharmaceutical companies. A total of seven
references reported on four studies. These included a Canadian
93/98/05 study that reported final height results in a full re-
port, one and two year growth results in one publication, final
height results in an abstract, and psychological adjustment mea-
sures in another publication (Rovet 1993). Two more trials re-
ported growth outcomes (Rosenfeld 1989; Quigley 2002). A final
study (Kollmann 1991) met the inclusion criteria in design, but
did not report data for the controlled phase of the trial. Both the
author and the sponsoring pharmaceutical company were con-
tacted for the data, but neither responded. Therefore, the data
from three studies were analysed, using the latest publication for
the Canadian study.
For a flow-chart of study selection in an adaptedQUOROM(qual-
ity of reporting of meta-analyses) version (Moher 1999) see Figure
1 under ’Additional figures’.
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Figure 1. Flow-chart of study selection in an adapted QUOROM (quality of reporting of meta-analyses)
version
Included studies
All included studies were randomised controlled trials with par-
allel designs. Only one study used a placebo control whereas the
others used a no treatment control. Therefore, the participants in
three of the four studies were aware of their treatment status. The
trials varied in the duration of the controlled phase. Although par-
ticipants in all four of the primary studies were treated until they
achieved final height, only the Canadian 93/98/05 study main-
tained a control group until final height, with a small subset of
girls participating in an addendum follow up. The Rosenfeld 1989
and Kollmann 1991 studies maintained a control group for one
year and the Quigley 2002 study maintained a placebo control for
18 months. Results from uncontrolled phases are not included in
this review.
Two studies were conducted in theUSA, one inCanada and one in
Germany. All included children had a diagnosis of TS confirmed
by karyotype. At enrolment, children varied between five years and
14 years old. In one study (Canadian 93/98/05) girls received a
weekly hGHdose of 0.30 mg/kg in six doses. In the Quigley 2002
study, two hGH doses were used: 0.27 mg/kg and 0.36 mg/kg;
each in three injections per week during the controlled phase. In
the Rosenfeld 1989 study, the weekly hGH dose was 0.375 mg/kg
administered in three injections. In the Kollmann 1991 study, two
doses were used and were computed on the basis of body surface
area. The doses were two international units (IU) per square meter
per week and three IU per square meter per week administered in
daily injections. Additional details of the studies can be found in
Characteristics of included studies.
The Quigley 2002 and Rosenfeld 1989 studies included treat-
ments in which hGH was combined with other agents. Results
from these treatments were not included in this review.
Risk of bias in included studies
The methodological quality of included studies was assessed using
the Jadad scale (Jadad 1996).
The included studies were of moderate quality. Additional infor-
mation is included in Characteristics of included studies. None of
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the studies described themethod of randomisation. The Canadian
93/98/05 study stratified girls for height relative to chronological
age at entry and randomly assigned them to GH treatment or no
treatment. The method of treatment allocation was not reported
in the other studies. In the Quigley 2002 study, participants and
investigators were blinded as to treatment status. Because the other
three studies used a no treatment control, blinding was not possi-
ble. Attrition was relatively high in the Canadian 93/98/05 study.
In the final report at protocol completion, it is reported that 19.7%
of the treated group, and 44.8% of the control group had dropped
out. TheQuigley 2002 study reported that eight participants (3%)
left the study within the first 180 days. Otherwise, attrition for
the placebo controlled phase of the study was not reported. The
Rosenfeld 1989 study reported that three participants (4%) with-
drew in the first 12 months. The Kollmann 1991study did not
report on attrition.
Effects of interventions
There is one trial that is still ongoing (NICHD). This trial, being
conducted in the USA, has not yet reported any results.
Final height
Only one study (Canadian 93/98/05) reported final height in
both recombinant growth hormone (hGH) treated and untreated
groups. Although the other included studies treated participants
until final height was achieved, they did not maintain a control
group until final height. In the Canadian 93/98/05 study, the girls
who were treated with hGH achieved a final height of 148 ± 6 cm
and the girls who did not receive treatment achieved a final height
of 141 ± 5 cm. This seven cm difference (95% confidence interval
(CI) 6.0 to 8) was statistically significant. Likewise, the treated
girls had a 1.6 ± 0.6 standard deviation change in their height stan-
dard deviation score (HtSDS) (age-specific Turner) from baseline
whereas the untreated girls had a 0.3 ± 0.4 SD change in their
HtSDS (age specific Turner) (mean difference (MD) 1.3 SD, 95%
CI 1.1 to 1.5). Normally, HtSDS does not change during growth
so the change in HtSDS for the treated girls indicates catch-up
growth.
Height standard deviation score (HtSDS)
Height standard deviation score can be measured at any point
during growth and indicates height relative to other children (or
adults) of the same age. One study (Canadian 93/98/05) reported
HtSDS scores for adult height at protocol completion. Ideally, one
would compare the participants with Turner syndrome (TS) to
normal girls of the same age as this is the comparison that is salient
to the girls themselves.However, this study reportedHtSDS using
a TS population standard. HtSDS (age specific Turner) was 1.2
SD (95% CI 1.0 to 1.5) greater in treated than untreated girls
and HtSDS (adult Turner) was 1.0 SD (95% CI 0.8 TO 1.3)
greater at protocol completion. These were statistically significant
differences.
Growth velocity (GV)
Three studies reported GV in cm per year. Two studies (Canadian
93/98/05; Rosenfeld 1989) reported GV after one year of treat-
ment. Treated girls grew approximately three cm more in the year
than did untreated girls (MD 3 cm per year, 95% CI 2 to 4).
One study (Quigley 2002) reported GV after 18 months of treat-
ment. GV was three cm per year (95% CI 2 to 3) greater in the
treated girls (0.36 mg/kg/wk dose) than in the untreated girls.
The Canadian 93/98/05 study reported GV after two years of
treatment that was two cm per year (95% CI 1.3 to 2.3) greater
in treated girls than in untreated girls. These results suggest that
growth improvements in treated girls does tend to decline over
longer treatment intervals.
Growth velocity standard deviation score (GVSDS)
Growth velocity standard deviation score represents how quickly
children are growing relative to their same age peers. As with
HtSDS it would be ideal to compare girls with TS with their nor-
mal peers. However, two studies (Canadian 93/98/05; Rosenfeld
1989) that report GVSDS used a TS population standard. These
two studies demonstrated that the GVSDS for the first year of
treatment in treated girls was approximately three SD greater
than in untreated girls (MD 3.2, 95% CI 2.8 to 3.6). One study
(Canadian 93/98/05) reported GVSDS after two years of treat-
ment showing that GVSDS was 1.6 SD greater (95% CI 1.0 to
2.2) in hGH treated girls than in untreated girls. As with the GV
results these results again suggest that increased growth declines
over longer treatment intervals.
Bone age
Bone age is a measure of skeletal maturity. If hGH treatment accel-
erates skeletal maturity, then growth benefits might be limited by
a shorter overall growth period (i.e., treated children might grow
faster, but stop growing sooner). If skeletal maturity is not acceler-
ated by hGH treatment, then changes in bone age should approx-
imate changes in chronological age such that a ratio of changes in
bone age to chronological age should be approximately one. One
study (Canadian 93/98/05) reported the ratio of changes in bone
age to changes in chronological age. After one year of treatment
the difference in the ratio was 0.2 (95% CI -0.03 to 0.4). After
two years of treatment the difference in the ratio was -0.1 (95%
CI -0.5 to 0.3). Although statistics are underpowered to conclude
that there is no difference in the ratios, hGH does not appear to
accelerate bone age as the ratio of bone age to chronological age
was approximately one at both time points in both treated and
untreated groups.
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Recombinant growth hormone (hGH) dose
Although the current review was not undertaken to evaluate the
effects of hGHdose, one included trial (Quigley 2002) did include
two hGH doses in addition to a placebo control. The two doses
were 0.27 mg/kg/wk and 0.36 mg/kg/wk. Over 18 months of
treatment the annualised growth velocity for girls on the two doses
did not significantly differ (MD 0.20, 95% CI -0.3 to 0.7). Other
studies that manipulated hGH dose, but that did not include a
placebo or no treatment control were not included in this review.
Therefore, no strong conclusions should be drawn about hGH
dose effects.
Psychological outcomes
Only one trial (Rovet 1993) reported on psychological outcomes
in relation to hGH treatment (see Appendix 3). This report was
based on tests performed on a sub-group of the participants in the
Canadian growth study (Canadian 93/98/05). These psycholog-
ical results are not presented more formally because the reported
results are a selection of the tests given to the children and their
parents. The selective reporting of results leaves in doubt the na-
ture of the unreported results. In addition, the reported results are
based on a subset of the girls who were participating in the trial at
the time and no explanation is offered for why the data from only
a subset of the participants were presented. The fact that these
evaluations are self-reports (or parent reports) in the context of
an unblinded study should also be considered. Bearing in mind
possible biases, the presented results suggest the possibility that
girls treated with hGH do have better psychological adjustment
than untreated girls.
Adverse effects
Reporting of adverse effects was minimal. Two of the included
trials (Quigley 2002 Canadian 93/98/05) mentioned adverse ef-
fects (see Appendix 2 ). In the placebo controlled phase of the
Quigley 2002 trial, otitis media occurred or worsened in 29% of
girls treated with hGH and in 13% of girls in the placebo group.
The longer-term adverse effects reported from this trial were not
reported separately for treatment groups. In the Canadian study
there were significant differences in ’treatment emergent’ adverse
effects between the treated and control groups (see Appendix 2 ).
D I S C U S S I O N
The results available suggest that recombinant growth hormone
(hGH) is effective in improving growth, final height and possi-
bly psychological adjustment in girls with Turner syndrome (TS).
Girls treated with hGH grew approximately three cmmore in one
year than did untreated girls and they grew approximately two
cm per year more than untreated girls after two years. Expressing
growth in growth velocity standard deviation (SD) scores reveals
similar results. It does appear that initial growth improvements
decline over longer treatment periods. However, there are insuffi-
cient data available to explicitly test this hypothesis.
The most important indicator of the efficacy of hGH for improv-
ing growth is the final height of women with TS who have been
treated with hGHduring their childhood. One study has reported
final height results that show that final height was seven cm greater
in women who had been treated with hGH than in women who
remained untreated. The treated women had a 1.6 SD change
in their height from baseline whereas the untreated women had
a 0.3 SD change, again indicating that the treated women had
catch up growth during treatment. Measures of bone age early in
treatment did not indicate that bone age was accelerated and the
eventual greater height of treated women supports the conclusion
that hGH treatment does not accelerate skeletal maturation.
The current review was focused on a stringent evaluation of the
efficacy of hGH in TS. For this reason evidence was limited to
randomised controlled trials in which a control group received ei-
ther placebo or no treatment. The presented results support the
efficacy of hGH, particularly in improvement of growth and final
height. It should be noted that these conclusions are supported by
findings from other research designs in which treatment and con-
trol groups were not randomised or treated groups are compared
with historical controls or with height predictions. Two of the in-
cluded trials (Quigley 2002; Rosenfeld 1998) treated participants
until final height but did not maintain the control group beyond
the period included in this review. Both of these studies reported
that the final height of treated women was improved relative to
expectations.
The one included trial that evaluated final height did not re-
port the average duration of hGH treatment. However, many cur-
rently available studiesmay not have treated participants optimally.
Current recommendations are that treatment should be started
early (ideally before age eight) and continue until final height is
achieved. This would correspond to treatment for approximately
eight years or longer. Most reported results are based on treatment
for shorter durations. In addition, two of the included trials in-
volved hGH injections three times per week. Current practice is
to inject hGH six or seven times per week. Therefore final height
improvements might be expected to be greater than reported here
if hGH treatment is started earlier and dosing is optimised.
There are concerns about attrition in the reported trials. The trial
reporting final height had lost approximately one third of the
participants at the time of reporting. It is possible that treated girls
who were achieving a poor response would be more likely to leave
the trial. Similarly, girls in the control group who were growing
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more slowly might be more likely to leave the trial. Both of these
kinds of attrition would bias results, albeit in opposite directions.
Adverse effects were minimally reported. In the included trials
there is little indication of serious adverse effects, however these
small trials are seriously underpowered to detect rare events. Over
longer term surveillance and outside the context of randomised
controlled trials it seems that adverse effects are rare, but can be
serious. Girls with TS may be at increased risk for a number of
conditions that might be affected by hGH treatment such as di-
abetes mellitus, slipped capital femoral epiphyses, idiopathic in-
tracranial hypertension, oedema and lymphoedema, or scoliosis
(Blethen 1996; Frisch 1997; GH Soc 2001).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The reported results indicate that recombinant growth hormone
(hGH) does improve growth and final height in girls with Turner
syndrome (TS). The doses used in the included trials were approx-
imately 0.3 to 0.375 mg/kg/wk (in one trial dose was computed
by surface area). In one trial conducted to final height, hGH treat-
ment increased final height in girls with TS by approximately seven
cm. Although treated women are taller than untreated women,
the final height achieved in treated women was approximately 148
cm. This is still below the normal range (i.e., more than 2 standard
deviations below the normal mean) for adult women. Therefore
it should be a matter for individual consideration as to whether
this expected height gain is substantial enough to merit frequent
or daily injections for probably 5 or more years. The cost of hGH
is also substantial and it is a matter of debate as to whether the
gains in height justify the expense. Finally, although serious ad-
verse effects may be rare, as TS may already increase the risk of
certain adverse effects, particular care should be taken to monitor
girls with TS who are treated with hGH.
Implications for research
The current review has focused on a strict evaluation of the ef-
ficacy of hGH primarily for improving growth and final height.
Within this context, additional trials that include a control group
until final height and that conduct an intention to treat analysis
would be very helpful to solidify the current findings. However, it
may already be felt that the merits of hGH are sufficiently demon-
strated that randomised control groups cannot be justified. If so,
it is unfortunate that those making treatment decisions (patients,
their parents and clinicians) will not know the extent to which
hGHmay affect final height under optimal treatment conditions.
Although results from randomised controlled trials cannot be di-
rectly applied to individuals, there are problems with interpreta-
tion of results from studies based on surrogate measures of height
improvement such as height prediction models (Taback 1999).
Despite the interest in the effects of hGH, treatment of short
stature in girls with TS does not generally consist only of hGH.
hGH is also often prescribed to girls with TS in combination
with other growth-stimulating agents such as oxandrolone. If the
efficacy of hGH has been adequately demonstrated, then focus
should move to trials in which combinations of agents, doses, and
timings are manipulated. Although there is merit in demonstrat-
ing short-term growth effects for such manipulations, these tri-
als should be conducted with unchanging conditions until final
height is achieved.
Existing evidence seems to indicate that growth and final height
can be improved in TS. Perhaps the more pressing research ques-
tion now is the cost-effectiveness of such treatment. To optimally
evaluate cost effectiveness requires a good estimate of clinical effec-
tiveness. This should not depend upon surrogate measures of effi-
cacy such as changes from predicted height or comparison with a
historical control, but should be based upon comparison between
randomised groups of patients who receive hGH treatment and
who do not. It may already be too late to collect more such data.
A full consideration of the costs and benefits of hGH treatment in
TS should include not only effects on height, but other outcomes
such as psychological or cognitive effects, which in the past have
received little attention in the evaluation ofhGH in TS.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Canadian 93/98/05
Methods RCT (Canada)
Allocation to treatment groups: randomised (stratified by chronological age and height at entry)
Blinding: unblinded
Comparability of treatment groups: no statistically significant differences at baseline in age, BA, height,
HtSDS, midparental height, or weight. Comparability may be compromised in final height comparisons
due to attrition
Method of data analysis: Differences between groups: 1 way ANOVA or Fisher’s exact test. Mean +/- SD
Sample size/power calculation: none
Attrition/drop-out: At protocol completion 19.7% of the GH treated group had withdrawn; 44.8% of
the control group had withdrawn
Participants For final height results starting n = 154
At protocol completion 104 achieved final height and formed the basis of the report. hGH: 61, Control:
43
Inclusion:
· Age 7 yr - 13 yr
· Documentation of diagnosis by karyotype
· Height : <10th centile on growth charts of National Centre for Health Statistics of the United States.
· Normal fasting serum levels of glucose
· Endogenous serum growth hormone of 8 µg/L on provocative or physiological testing
· All forms of TS and variant included, including Y chromosome mosaic forms if gonadal remnants
surgically removed
· Annualised GV < 6 cm/yr during 6 mo pre-randomisation period
Setting: not specified
Interventions 1. hGH: 0.30 mg/kg six times weekly (Humatrope®). Maximum dose 15mg
2. No Treatment
Girls with primary ovarian failure received oestrogen/progesterone treatment starting age 13
Outcomes · Final height
· Height change from baseline (HtSDS)
· Change in BA
(for psychological adjustment outcomes see Rovet 1993 study below)
Notes Generalisability: participants seem representative of target population
Outcome measures: final height, HtSDS and BA appropriate (although use TS standard)
Inter-centre variability: not assessed.
Conflict of interests: support from Eli Lilly Canada.
Final height = growth rate < 2 cm/yr and bone age >= 14 years
Risk of bias
Item Authors’ judgement Description
17Recombinant growth hormone for children and adolescents with Turner syndrome (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Canadian 93/98/05 (Continued)
Allocation concealment? Yes A - Adequate
Kollmann 1991
Methods RCT (Germany)
Allocation to treatment groups: not described
Blinding: no information
Comparability of treatment groups: no statistical comparisons of baseline characteristics. 2 IU/m2 group
slightly older, taller, and heavier at baseline
Method of Data analysis: no statistical analysis presented
Sample size/power calculation: group sizes computed to detect an effect using a one-sided test
Attrition/drop-out: not reported
Participants 84 enrolled
2 IU group: 29
3 IU group: 26
No treatment: 29
Include:
· prepubertal
· age >= 5 and <= 14
· height <= 2 SD for age according to Swiss standard
Interventions 1. hGH 2 IU/m2/wk (5.18 mg/m2/wk) in daily injections
2. hGH 3 IU/m2/wk (7.77 mg/m2/wk) in daily injections
3. No treatment
Outcomes · GV
· HtSDS (normal population standard)
· Ht SDS (TS population standard)
· Changes in BA/Changes in CA
· Adverse Effects
Notes No complete data for any outcome are presented. Therefore, no data from this trial are included in the
current review
Generalisability: Inclusion crtieria are objective (although no description of types of TS karotypes were
included). Participants seem representative
Outcome measures: appropriate
Conflict of interests: Eli Lilly Study Group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Quigley 2002
Methods RCT (USA)
Allocation to treatment groups: not described
Blinding: Patients and investigators blinded to treatment status, observer for BA analysis blinded
Comparability of treatment groups: No statistically significant differences in baseline measures of GV or
height, other measures appear similar except that placebo/placebo group (group 5) older, with greater BA
and taller at baseline
Method of data analysis: hypothesis tests: one-way ANOVA, Chi Square, Fisher’s exact test for baseline
measures; ANCOVA, stepwise regression and backward elimination models used for post-manipulation
results
Sample size/power calculation: no mention
Attrition/drop-out: 8 left study within first 180 days, 133 (57%) not included in near FH analysis,
otherwise not reported
Participants 232 enrolled
stratified by age (5-8, >8-10, > 10-12, > 12) then randomised
Baseline data reported for n=224 who received hGH for 180 days
Group 1: n=45
Group 2: n=47
Group 3: n=49
Group 4: n=42
Group 5: n=41
99 in analysis of near FH
Include:
· TS, karyotypically proven
· Age =>5 years
· BA =< 12 years
· Prepubertal
· < 10th percentile for height on National Centre for Health Statistics (NCHS) standard
· GV < 6 cm/yr
Exclude:
· Presence of any Y chromosomal component
· Concurrent treatment with any agent that might influence growth
· Clinically significant systemic illness
setting: multicentre, otherwise not specified
Interventions 1. hGH 0.27 mg/kg/wk with oral placebo
2. hGH 0.27 mg/kg/wk with low dose oestrogen
3. hGH 0.36 mg/kg/wk with oral placebo
4. hGH 0.36 mg/kg/wk with low dose oestrogen
5. Placebo injection with oral placebo
current review included groups 1, 3, & 5 for 1st 18 months only (controlled phase)
Injections 3x/wk for first 18 mo, thereafter 6x/wk
(Humatrope®)
Oestrogen dose based on age and weight.
Open label sex steroid replacement at age 13.5 yr.
Group 5 maintained for 18 months thereafter all treated with hGH (joined group 3)
Outcomes · GV
· near FH (not reported in current review because no untreated group)
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Quigley 2002 (Continued)
Notes Generalisability: Inclusion criteria are objective and seem representative
Outcome measures: measures appropriate
Inter-centre variability: not assessed - 50 sites
Conflict of interests: Eli Lilly sponsored
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Rosenfeld 1989
Methods RCT (USA)
Allocation to treatment groups: Randomised, but method not discussed
Blinding: no information
Comparability of treatment groups: Comparable in pretreatment growth. Other variables not compared
Method of Data analysis: no statistical comparisons between groups
Attrition/drop-out: 3 withdrawn within first 12 months
Participants n = 71, age 9.3 yr (4.7 - 12.4)
hGH: 17
GV: 4.5 ± 0.8
GVSDS: 0.5 ± 0.8
Control: 18
GV: 4.2 ± 1.1
GVSDS: 0.2 ± 1.2
OX: 19
GV: 4.1 ± 1.9
GVSDS: 0.2 ± 1.0
hGH + OX: 17
GV: 4.3 ± 0.9
GVSDS: 0.2 ± 0.9
Only data from hGH and control groups included in current review
height >=1SD below mean for age
pretreatment growth rate < 6cm/yr
normal thyroid function
provocative serum GH >= 7 ng/ml
Setting: not specified
Interventions 1. Met-hGH: 0.125 mg/kg/ 3x/wk intramuscular
12 - 20 mo
2. Control: no treatment
3. Oxandrolone (OX) 0.125 mg/kg/day
4. Combination OX and hGH doses as above
Outcomes · Growth velocity
· Growth velocity SD relative to TS standard
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Rosenfeld 1989 (Continued)
Notes Generalisability: Subjects appear representative of target group
Outcome measures: Growth velocity and TS standardised growth velocity are appropriate, although
normal population standard would be more useful
Inter-centre variability: not assessed
Conflict of interests: support from Genentech
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Rovet 1993
Methods RCT (Canada)
Allocation to treatment groups: Method of randomisation not reported.
Blinding: none reported
Comparability of treatment groups: Baseline comparability of groups still participating was reported but
the comparability of sub-groups as analysed was not reported
Method of data analysis: Analysis not on an ITT basis. Point estimates and CI of differences was not
reported. Significance levels estimated using ANOVA. No corrections for multiple comparisons
Sample size / power calculations: no power calculations
Attrition / drop-out: 49% drop-out rate from those still participating in trial
Subjective ratings by children and parents may be affected by the unblinded nature of the study. Consider
possible effects such as justification of effort
Participants 122 enrolled
95 participating at time of evaluation (51 hGH; 44 no treat)
86 compliant
65 available for evaluation at 18 months
48 in analysis (28 hGH; 20 no treat)
Inclusion:
· Turner syndrome (included Y mosaic forms provided gonadal remnants removed)
· Age range 7 - 12 yr 11 mo
· Height =<10th centile on TS chart
· Documented height velocity for previous 6 months
· Normal fasting serum glucose
· Endogenous growth hormone >= 8 mg/l on provocative physiological testing
Baseline characteristics of 95 participating:
· Age: hGH: 10.8 ±0.2, no treat: 10.7 ± 0.2
· BA: hGH: 9.0 ± 0.2, no treat: 8.8 ± 0.2
· Ht (cm): hGH: 121.0 ± 1.2, no treat: 120.1 ± 1.1
Exclude:
· Coincident disease likely to influence growth
· Previous radiation to CNS / spinal axis
· Previous treatment with adrenal androgens, oestrogen or hGH
· Untreated hypothyroidism
· started oestrogen treatment (in current trial)
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Rovet 1993 (Continued)
Interventions 1) hGH: 0.05 mg/kg sc 6 evenings / week. Maximum weekly dose of 15 mg. (Humatrope®)
2) No treatment
Length of treatment: 18 months
Other interventions: none reported for this sub-group
Outcomes · Olson’s FACES III (protectiveness and stability)
· Piers Harris self concept test (child self report; global self-concept and 6 subscales)
· Achenbach’s Child Behaviour Checklist (completed by parents)
· Youth Self-Report (child)
· GV (see Canadian 1993/1998)
Not all outcomes were reported. Results from non-reported outcomes are unknown
Notes Generalisability: Inclusion and exclusion criteriawere defined. Analysis limited to 48out of 95participating
in trial (51%) who had been followed up for 18 months. Therefore results may not be representative
Outcome measures: Limited to psychological assessment with subjective ratings by child and parents in
unblinded study. No objective confirmation of reports. Study not blinded, so cannot exclude differing
input to those on active compared to no treatment (whether from parents / researchers). Short term
outcomes (18 months treatment). Dropout analysis apparently based on 65 participants among whom the
dropout was considerably greater in treated than untreated. This could bias results although evaluation of
dropouts from the final analysis appears not to have been conducted
Inter-centre variability: not assessed (13 sites)
Conflict of interests: support from Eli Lilly, Canada
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
TS: Turner syndrome; GV: growth velocity; BA: bone age; IU: International Units: HtSDS: height standard deviation score. Interim
HtSDS denotes a standard deviation score measured at some point before growth is complete.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arnal 1988 No untreated group
Bertelloni 2000 Not RCT
Bertrand 1996 No untreated group
Chernausek 2000 No untreated group
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(Continued)
De Schepper 1994 No untreated group
Gyorgy 1993 Not RCT
Haeusler 1995 No untreated group
Heinrichs 1995 No untreated group
Holland 1991 Duplicate publication with Canadian study
Job 1991 No untreated group
Johnston 2001 No untreated group
Keizer-Schrama 1999a No untreated group
Keizer-Schrama 1999b No untreated group
Kollmann 1990 Abstract - No data presented
Lin 1988 No untreated group
Mahachoklertwattana Not RCT
Massa 1995 No untreated group
Mazzanti 1995 Not RCT
Nilsson 1996 No untreated group
Rocchiccioli 1994 Not RCT
Rongen-Westerlaken No untreated group
Rosenfeld 1992a No untreated group at final height
Rosenfeld 1992b No untreated group after 12-24 months
Rosenfeld 1998 No untreated group at final height
Ross 1997 No growth outcome reported
Sas 1999a No untreated group
Sas 1999b No untreated group
Sas 1999c No untreated group
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(Continued)
Sippell 1991 Not RCT
Stahnke 1992 No untreated group
Stahnke 1999 No untreated group
Takano 1989 Not RCT
Takano 1990 No untreated group
Takano 1993a No untreated group
Takano 1993b No untreated group
van Teunenbroek 1996 No untreated group
van Teunenbroek 1997 No untreated group
Vanderschueren 1990 No untreated group
Werther 1991 No untreated group
Werther 1993 No untreated group
Werther 1995 No untreated group
Characteristics of ongoing studies [ordered by study ID]
NICHD
Trial name or title Effect of biosynthetic growth hormone and/or ethinyl estradiol on adult height in patients with Turner
syndrome
Methods
Participants TS by karotype (no Y chromosome component)
>= 5 years old
below 10th percentile in height for age (for additional info see http://clinicaltrials.gov)
Interventions 1. low dose estrogen
2. growth hormone
3. low dose estrogen and growth hormone
4. placebo
Outcomes adult height
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NICHD (Continued)
Starting date 09/1987
Contact information NICHD 9000 Rockville Pike
Bethesda, Maryland 20892 USA
prpl@mail.cc.nih.gov
Notes Recruitment has stopped, but trial is expected to run another 2-4 years as participants finish growth
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D A T A A N D A N A L Y S E S
Comparison 1. Growth hormone versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Final height 1 Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 Final height in cm 1 Mean Difference (IV, Random, 95% CI) Not estimable
1.2 Change in final height
standard deviation score from
baseline (relative to Turner
syndrome population)
1 Mean Difference (IV, Random, 95% CI) Not estimable
2 Growth velocity (growth velocity
in cm per year)
2 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Growth velocity after one
year of treatment
1 Mean Difference (IV, Random, 95% CI) Not estimable
2.2 Growth velocity after 18
months of treatment
1 Mean Difference (IV, Random, 95% CI) Not estimable
3 Growth velocity standard
deviation score (relative to
Turner syndrome population)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Growth velocity standard
deviation score after one year of
treatment
1 Mean Difference (IV, Random, 95% CI) Not estimable
Comparison 2. Growth velocity for growth hormone doses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Higher dose growth hormone
versus lower dose growth
hormone
1 94 Mean Difference (IV, Random, 95% CI) 0.20 [-0.25, 0.65]
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Analysis 1.1. Comparison 1 Growth hormone versus placebo or no treatment, Outcome 1 Final height.
Review: Recombinant growth hormone for children and adolescents with Turner syndrome
Comparison: 1 Growth hormone versus placebo or no treatment
Outcome: 1 Final height
Study or subgroup Growth hormone No treatment
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Final height in cm
Canadian 93/98/05 61 147.5 (6.1) 43 141 (5.4) 6.50 [ 4.28, 8.72 ]
2 Change in final height standard deviation score from baseline (relative to Turner syndrome population)
Canadian 93/98/05 61 1.6 (0.6) 43 0.3 (0.4) 1.30 [ 1.11, 1.49 ]
-10 -5 0 5 10
Favours no treatment Favours GH
Analysis 1.2. Comparison 1 Growth hormone versus placebo or no treatment, Outcome 2 Growth velocity
(growth velocity in cm per year).
Review: Recombinant growth hormone for children and adolescents with Turner syndrome
Comparison: 1 Growth hormone versus placebo or no treatment
Outcome: 2 Growth velocity (growth velocity in cm per year)
Study or subgroup Growth hormone Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Growth velocity after one year of treatment
Rosenfeld 1989 17 6.6 (1.2) 18 3.8 (1.1) 2.80 [ 2.04, 3.56 ]
2 Growth velocity after 18 months of treatment
Quigley 2002 49 6.8 (1.1) 41 4.2 (1.1) 2.60 [ 2.14, 3.06 ]
-4 -2 0 2 4
Favours control Favours GH
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Analysis 1.3. Comparison 1 Growth hormone versus placebo or no treatment, Outcome 3 Growth velocity
standard deviation score (relative to Turner syndrome population).
Review: Recombinant growth hormone for children and adolescents with Turner syndrome
Comparison: 1 Growth hormone versus placebo or no treatment
Outcome: 3 Growth velocity standard deviation score (relative to Turner syndrome population)
Study or subgroup Growth hormone Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Growth velocity standard deviation score after one year of treatment
Rosenfeld 1989 17 3.1 (1.2) 18 -0.1 (1) 3.20 [ 2.47, 3.93 ]
-4 -2 0 2 4
Favours no treatment Favours GH
Analysis 2.1. Comparison 2 Growth velocity for growth hormone doses, Outcome 1 Higher dose growth
hormone versus lower dose growth hormone.
Review: Recombinant growth hormone for children and adolescents with Turner syndrome
Comparison: 2 Growth velocity for growth hormone doses
Outcome: 1 Higher dose growth hormone versus lower dose growth hormone
Study or subgroup 0.36 mg/kg/wk 0.27 mg/kg/wk
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Quigley 2002 49 6.8 (1.1) 45 6.6 (1.1) 100.0 % 0.20 [ -0.25, 0.65 ]
Total (95% CI) 49 45 100.0 % 0.20 [ -0.25, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
-4 -2 0 2 4
Favours lower dose Favours higher dose
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A P P E N D I C E S
Appendix 1. Search strategy
Search terms
Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp =
exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw =
text word; pt = publication type; sh = MeSH; adj = adjacent.
1 explode “Somatropin”/ all subheadings
2 somatropin*
3 somatotropin*
4 somatotrophin*
5 growth hormone
6 genotropin*
7 humatrope*
8 norditropin*
9 saizen*
10 zomacton*
11 nutropin*
12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11
13 child*
14 adolescen*
15 #13 or #14
16 #12 and #15
17 “TURNER-SYNDROME”/ all subheadings
18 #17 and #16
19 RANDOMIZED-CONTROLLED-TRIAL IN PT
20 CONTROLLED-CLINICAL-TRIAL IN PT
21 RANDOMIZED-CONTROLLED-TRIALS
22 RANDOM-ALLOCATION
23 DOUBLE-BLIND-METHOD
24 SINGLE-BLIND-METHOD
25 #19 or #20 or #21 or #22 or #23 or #24
26 CLINICAL-TRIAL IN PT
27 explode CLINICAL-TRIALS/ all subheadings
28 (CLIN* near TRIAL*) in AB,TI
29 (singl* or doubl* or trebl* or tripl*) near (blind* or mask*)
30 placebo*
31 (RANDOM*) in TI,AB
32 RESEARCH-DESIGN
33 #26 or #27 or #28 or #29 or #30 or #31 or #32
34 #33 not #25
35 TG = “COMPARATIVE-STUDY”
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(Continued)
36 explode “Evaluation-Studies”/ all subheadings
37 “Follow-Up-Studies”
38 “Prospective-Studies”
39 (control* or prospective* or volunteer*) in ti,ab
40 #35 or #36 or #37 or #38 or #39
41 #40 not (#25 or #34)
42 #25 or #34 or #41
43 #18 and #42
Appendix 2. Reported adverse effects
Study Effect Number or Proportion
Quigley 2002 (placebo controlled phase) Otitis Media occurred or worsened 29% ofGH treated; 13% of placebo treated
Rosenfeld 1989 No discussion of adverse effects
Canadian 2005 Surgical procedures; otitis media; ear disor-
ders; joint disorder; respiratory disorder; si-
nusitis; goiter
37 of GH treated, 17 of untreated; 35 GH
treated, 17 of untreated; 15 of GH treated,
4 of untreated; 10 of GH treated, 2 of un-
treated; 8 of GH treated, 1 of untreated;
14 of GH treated, 4 of untreated; 0 of GH
treated, 4 of untreated
Rovet 1993 No discussion of adverse effects
Kollmann 1991 No discussion of adverse effects by treat-
ment groups
Appendix 3. 18 months psychological results from Canadian study (Rovet et al, 1993)
Psych. Measure GH treated Untreated control treated v control
Global self-concept (self-re-
port)
76.5 +/- 18.9 64.4 +/- 21.7 p = 0.001
Appearance (self-report) 67.0 +/- 24.5 55.7 +/- 24.9 p = 0.08
Intelligence (self-report) 75.0 +/- 23.8 56.2 +/- 25.2 p = 0.01
Peer Relations (self-report) 66.4 +/- 27.4 32.4 + 25.6 p = 0.001
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(Continued)
Friendships (mother rating) 3.15 +/- 0.6 2.72 +/- 0.83 p = 0.05
Popularity (mother rating) 66.4 +/- 27.4 32.4 +/- 25.6 p = 0.001
Teasing (parent rating) 0.69 +/- 0.55 1.05 +/- 0.61 p = 0.05
Hyperactivity (mother rating ) 59.6 +/- 7.6 65.2 +/- 8.0 p = 0.05
Protectiveness (mother rating) 1.10 +/- 1.31 0.63 +/- 0.9 p = .10
WH A T ’ S N E W
Last assessed as up-to-date: 30 July 2006.
Date Event Description
3 November 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 4, 2002
Review first published: Issue 3, 2003
Date Event Description
31 July 2006 New search has been performed 38 publications were identified by the updated searches. One full record was
retrieved from the updated search
C O N T R I B U T I O N S O F A U T H O R S
LOUISE BAXTER: selection of studies, data extraction, drafting of update review, data analysis, data presentation
JACKIE BRYANT: selection of studies, data extraction, drafting of protocol and review, data analysis, data presentation
CAROLYN CAVE: selection of studies, data extraction, drafting of protocol and review, data analysis, data presentation
RUAIRIDH MILNE: drafting of protocol/review, data presentation
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Wessex Institute, University of Southampton, UK.
External sources
• No sources of support supplied
N O T E S
An additional reviewer has been added to the review (L Baxter).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adolescent; Body Height; Growth Disorders [∗drug therapy; etiology]; Growth Hormone [∗therapeutic use]; Randomized Controlled
Trials as Topic; Recombinant Proteins [therapeutic use]; Turner Syndrome [∗complications]
MeSH check words
Child; Female; Humans
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